Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients

British Journal of Dermatology(2023)10.1093/bjd/ljad369Source: DataRank Database

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients is a research paper published in British Journal of Dermatology (2023). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 8.10)OA: greenTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (33)

F. Lombart,G. Chaby ORCID,A. Dadban ORCID,S. Debarbieux ORCID,M. Viguier

Live enrichment

PubMed:37792727 PMC:PMC13077217 OpenAlex:https://openalex.org/W4387327450

French Study Group on Autoimmune Bullous Diseases

NIH

FWCI

8.10

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13077217/

publisherhttps://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad369/54566149/ljad369.pdf

publisherhttps://academic.oup.com/bjd/article-pdf/190/2/258/58992364/ljad369.pdf

journalhttps://doi.org/10.1093/bjd/ljad369

Fields of Study

Autoimmune Bullous Skin DiseasesDermatology and Skin DiseasesPeripheral Neuropathies and Disorders

MeSH Terms

OmalizumabCollagen Type XVIIAdultAgedAged, 80 and overAutoantibodiesAutoantigensHumansImmunoglobulin EMiddle AgedPemphigoid, BullousRetrospective StudiesNon-Fibrillar CollagensYoung Adult

Keywords

OmalizumabMedicineBullous pemphigoidRetrospective cohort studyDermatologyPemphigoidPediatricsInternal medicineImmunoglobulin EImmunology

Sustainable Development Goals

SDG 0: Good health and well-being